A polymorphism in NFKB1 is associated with improved effect of interferon-α maintenance treatment of patients with multiple myeloma after high-dose treatment with stem cell support

Por Vangsted, Annette J., Klausen, Tobias W., Gimsing, Peter, Andersen, Niels F., Abildgaard, Niels, Gregersen, Henrik, Vogel, Ulla
Publicado em 2009

Common Genetic Variants in 11q13.3 and 9q22.33 Are Associated With Molecular Subgroups of Multiple Myeloma

Por Erickson, Stephen W., Stephens, Owen W., Chavan, Shweta S., Tian, Erming, Epstein, Joshua, Barlogie, Bart, Heuck, Christoph J., Vangsted, Annette J.
Publicado no Leukemia (2015)

No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma

Por Vangsted, Annette J, Søeby, Karen, Klausen, Tobias W, Abildgaard, Niels, Andersen, Niels F, Gimsing, Peter, Gregersen, Henrik, Vogel, Ulla, Werge, Thomas, Rasmussen, Henrik B
Publicado em 2010

A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: Results from the IMMEnSE consortium and meta-analysis

Por Ríos-Tamayo, Rafael, Lupiañez, Carmen Belén, Campa, Daniele, Hielscher, Thomas, Weinhold, Niels, Martínez-López, Joaquin, Jerez, Andrés, Landi, Stefano, Jamroziak, Krzysztof, Dumontet, Charles, Wątek, Marzena, Lesueur, Fabienne, Reis, Rui Manuel, Marques, Herlander, Jurczyszyn, Artur, Vogel, Ulla, Buda, Gabriele, García-Sanz, Ramón, Orciuolo, Enrico, Petrini, Mario, Vangsted, Annette J, Gemignani, Federica, Försti, Asta, Goldschmidt, Hartmut, Hemminki, Kari, Canzian, Federico, Jurado, Manuel, Sainz, Juan
Publicado no Oncotarget (2016)